Abstract
18 patients with symptomatic essential thrombocythaemia were treated with recombinant alpha interferon (2a or 2b). Subcutaneous dosage regimens, which were well-tolerated, selectively lowered the platelet count and relieved symptoms in all patients, whether previously treated or untreated. Recombinant alpha-interferon may offer a non-leukaemogenic alternative therapy for these patients.
| Original language | English (Ireland) |
|---|---|
| Number of pages | 3 |
| Journal | Lancet |
| Volume | 2 |
| Issue number | 8602 |
| Publication status | Published - 1 Jul 1988 |
Authors (Note for portal: view the doc link for the full list of authors)
- Authors
- Giles FJ, Singer CR, Gray AG, Yong KL, Brozovic M, Davies SC, Grant IR, Hoffbrand AV, Machin SJ, Mehta AB